Sandoz Group Ag S/Adr (SDZNY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now hand over to Craig Marks, head of investor relations, for his opening remarks. Thank you and welcome to the Sandoz full year results call for 2025. Earlier today, we published a press release and an accompanying presentation on our website, which will follow on today's call. You can find these documents at Sandoz.com stroke investors. Joining me on today's call are Richard Seynod, Chief Executive Officer, and Remco Steenbergen, Chief Financial Officer. Please turn to slide two. Our results announcement, presentation, and discussion include forward-looking statements. Please see our disclaimer here. Please turn to slide three. Richard will begin today's presentation with the highlights of 2025, followed by an update on the business. Remco will cover the financial performance, as well as the guidance for 2026. Following the wrap-up of the presentation, we'll be happy to take your questions. And with that, I will now hand over to Richard. Please turn to slide four. Thank you, Craig. And hello, everyone. It is a pleasure to welcome you all on the call today. Our second full year as an independent company was a very successful one, and I'm proud to share our achievements. 2026 is a significant year for us as we celebrate some very special anniversaries that reflect our legacy and our future. 20 years ago, Sandoz pioneered the world's first biosimilar, opening the door to advanced treatments for more patients and setting new standards for access and affordability. 80 years ago, we transformed a brewery into a penicillin factory, making antibiotics more accessible and saving millions of lives. Kundal remains Europe's last major end-to-end producer of penicillins, a legacy of reliability and...